2-甲氧基雌二醇对骨髓瘤细胞系增殖与凋亡的影响

为了探讨2-甲氧基雌二醇对骨髓瘤细胞系增殖及凋亡的影响,并观察其与地塞米松、反应停、三氧化二砷、唑仑膦酸钠等药物联合时的协同作用,采用台盼蓝染色法检测细胞活力,应用BrdU掺入法检测浆细胞标记指数(PCLI),DNA片段原位末端标记(TUNEL法)检测凋亡细胞.药物协同作用判断标准按金氏公式计算Q值.结果表明,7株骨髓瘤细胞系NCI-H929、HS-sultan、KM3、SK0-007、CZ-1、U266、LP-1经1、4、8、12、16 μmol/L 2-甲氧基雌二醇分别作用12、24、36和48小时后细胞活力明显受抑制,呈现时间剂量依赖性,经统计学分析,差异显著(P＜0.05).各细胞系对2-甲氧基雌二醇敏感性不同,其IC50介于(20.8±0.27)μmol/L与(34.1±0.57)μmol/L之间.1、4、8、12、16 μmol/L 2-甲氧基雌二醇分别作用12、24、36和48小时可诱导骨髓瘤细胞系凋亡,凋亡率介于9%-33%之间,呈现时间和剂量依赖性,经统计学分析,差异显著(P＜0.05).经12 μmol/L 2-甲氧基雌二醇作用24小时后浆细胞标记指数(PCLI)由作用前平均(30.14±4.28)%下降到作用后的(14.71±6.27)%,差异显著(P＜0.05).2-甲氧基雌二醇与药物联合作用后计算Q值介于1.13-1.43之间,具有协同作用.结论2-甲氧基雌二醇可抑制骨髓瘤细胞生长,并可诱导骨髓瘤细胞凋亡,与地塞米松、反应停、三氧化二砷、唑仑膦酸钠联合使用具有协同作用.

Effect of 2-Methoxyestradiol on Proliferation and Apoptosis of Myeloma Cell Lines

The objective was to explore the in vitro effects of growth inhibition and apoptosis induction of 2-methoxyestradiol (2ME2), an estrogen derivative, on seven myeloma cell lines NCI-H929, HS-sultan, KM3, SKO-007, CZ-1, U266 and LP-1and to observe its synergistic effects in combination with some other drugs, such as dexamethasone, As(2)O(3), thalidomide and zoledronic acid. Seven myeloma cell lines NCI-H929, HS-sultan, KM3, SKO-007, CZ-1, U266 and LP-1 were cultured at different concentrations with or without dexamethasone, As(2)O(3), thalidomide and zoledronic acid. Cell viability was assessed by trypan blue assay, plasma cell labeling index (PCLI) was detected by BrdU assay, terminal-deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay were used to determine apoptosis cells in situ. Synergistic effects of 2ME2 in combination with other drugs were judged by King's formula. The results showed that after treatment with 1, 4, 8, 12, 16 micromol/L 2ME2 at 12, 24, 36 and 48 hours respectively, 2ME2 caused a dose- and time-dependent inhibition of the cell viability. The concentration of 50% growth inhibition (IC(50)) was between (20.8 +/- 0.27) and (34.1 +/- 0.57) micromol/L. After treatment with 12 micromol/L 2ME2 within 24 hours, 2ME2 led to a progressive decline in the fraction of S-phase cells by BrdU assay, plasma cell labeling index (PCLI) declined from (30.14 +/- 4.28)% to (14.71 +/- 6.27)% (P < 0.05). After treatment with 1, 4, 8, 12, 16 micromol/L 2ME2 at 12, 24, 36 and 48 hours respectively, 2ME2 can induce a dose- and time-dependent apoptosis of myeloma cell lines. The percentage of apoptosis was between 9% - 33% (P < 0.05). Q value of synergistic effects was between 1.13 to 1.43. It is concluded that 2ME2 can inhibit proliferation and induce apoptosis of myeloma cell lines and has synergistic effects with dexamethasone, As(2)O(3), thalidomide and zoledronic acid.